Welcome to our dedicated page for Chemomab Therapeutics Ltd. SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemomab Therapeutics Ltd. filings document a foreign private issuer focused on clinical-stage biotechnology and traded through American Depositary Shares. Its Form 6-K reports furnish operating updates, quarterly and year-end financial results, unaudited consolidated financial statements, management discussion and analysis, and press releases on the nebokitug program in primary sclerosing cholangitis.
The filing record also covers ADS and capital-structure matters, including at-the-market offering arrangements, ADS ratio-adjustment disclosures, shelf registration and equity incentive registration references, and annual general meeting materials. Proxy-related filings describe shareholder voting procedures for ADS holders, director elections, compensation policy approval, authorized share capital amendments, auditor re-appointment, quorum matters, and governance under Israeli company law.
Morgan Stanley and subsidiary file Schedule 13G/A (Amendment 1) for Chemomab Therapeutics (CMMB) covering an ownership change effective 07/31/2025.
- Morgan Stanley reports 13,213,260 ordinary shares/ADS held with shared voting & dispositive power, equal to 3.2 % of Chemomab’s outstanding class.
- Morgan Stanley & Co. LLC reports 9,275,360 shares (shared voting & dispositive power) representing 2.2 % of the class.
- Both filers certify that they have ceased to be beneficial owners of more than 5 % of the issuer’s equity, triggering this amendment.
- Reporting persons are classified as HC/CO (holding company) and BD/CO (broker-dealer) under Item 3.
- No other persons have sole voting or dispositive authority; all powers are shared within the Morgan Stanley reporting units.
- The filing includes a Joint Filing Agreement (Ex. 99.1) and Item 7 subsidiary information (Ex. 99.2).
The amendment signals a reduction of Morgan Stanley’s aggregate position below the 5 % regulatory threshold, though the group still retains a meaningful minority stake.
Schedule 13G filing dated 06/30/2025 shows Morgan Stanley and subsidiary Morgan Stanley & Co. LLC have exceeded the 5 % threshold in Chemomab Therapeutics Ltd. (CMMB).
- Morgan Stanley reports 32,282,680 ordinary shares/ADS, representing 8.4 % of the outstanding class.
- Morgan Stanley & Co. LLC separately holds 28,786,680 shares or 7.5 %.
- Both entities report shared voting and dispositive power; no sole authority is listed.
- Filed under Rule 13d-1(b) as a broker-dealer/holding company, signalling a passive investment rather than a control bid.
- Cover pages classify the parent as “HC, CO” and the subsidiary as “BD, CO.”
- Signatures by authorised signatory Christopher O’Hara are dated 08/07/2025.
The disclosure increases institutional visibility and liquidity for CMMB but contains no operational or strategic changes.
OrbiMed Israel and affiliated entities have filed Amendment No. 5 to Schedule 13D reporting their exit from a significant ownership position in Chemomab Therapeutics Ltd (NASDAQ: CMMB). The filing indicates that following a major transaction, the reporting persons have ceased to be beneficial owners of more than 5% of the company's shares.
Key details of the transaction and current holdings:
- On June 18, 2025, OrbiMed Israel Partners (OIP) sold 1,610,000 American Depositary Shares at $1.10 per ADS
- Current holdings include 131,273 ADSs, 28,817 Warrants, and 809,717 Pre-Funded Warrants
- Total beneficial ownership now represents approximately 4.8% of outstanding shares
The reporting group includes OrbiMed Israel GP Ltd, OrbiMed Israel BioFund GP Limited Partnership, Carl L. Gordon, and Erez Chimovits. The holders maintain registration rights for their remaining securities under a previously established Registration Rights Agreement.